Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Bio2RDF identifier
NCT01243476
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT01243476
identifiers.org URI
acronym [clinicaltrials_vocabulary:acronym]
SINTRA-REV
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
Trial Design:
Th ...... le is included in the trial).
brief title [clinicaltrials_vocabulary:brief-title]
Study of REVLIMID (Lenalidomid ...... Risk Myelodysplastic Syndrome
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2020-01-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
General summary of myel ...... the AR with Lenalidomide.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2010-11-17T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
5q deletion
lenalidomide
myelodysplastic syndrome
red blood cells transfusion
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2015-03-05T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT01243476
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Multicenter, Randomized, Doubl ...... thout the Need of Transfusion.
org study id [clinicaltrials_vocabulary:org-study-id]
SINTRA-REV
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2016-01-01T00:00:00Z
reference [clinicaltrials_vocabulary:reference]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
2009-013619-36
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2010-01-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2015-03-01T00:00:00Z
identifier
clinicaltrials:NCT01243476
title
Study of REVLIMID (Lenalidomid ...... Risk Myelodysplastic Syndrome
@en